Необязательная аналитика продукта
С вашего разрешения мы используем ограниченную аналитику с защитой конфиденциальности, чтобы понять, какие исследовательские сценарии работают. Мы не используем рекламные трекеры или запись сеансов. Этот выбор можно изменить в настройках. Прочитайте Политику конфиденциальности.
Pool Corporation's published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $6.3B | |
|---|---|---|
| Revenue (ttm) | 5.4B | |
| Net income (ttm) | 393.7M | |
| EPS (ttm) | $10.8 | |
| Shares out | 36.3M | |
| P/E (trailing) | 18.0x | |
| P/E (forward) | 17.1x | |
| Dividend | $5.20 (2.69%) | |
| Volume | 668,972 | |
| Beta | 1.04 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $5.30B | $6.18B | $5.54B | $5.31B | $5.29B | -0.0% |
| Gross profit | $1.62B | $1.93B | $1.66B | $1.58B | $1.57B | -0.7% |
| Operating income | $832.8M | $1.03B | $746.6M | $617.2M | $580.2M | -8.6% |
| Net income | $650.6M | $748.5M | $523.2M | $434.3M | $406.4M | -11.1% |
| EPS (diluted) | $15.97 | $18.70 | $13.35 | $11.30 | $10.85 | -9.2% |
| EBITDA | $862.8M | $1.06B | $786.7M | $662.7M | $631.8M | -7.5% |
| R&D | — | — | — | — | — | — |
| SG&A | $784.3M | $907.6M | $913.5M | $958.1M | $992.3M | +6.1% |
Recent company headlines from major financial publishers.
The modal expected path where non-discretionary maintenance demand provides a stable baseline, while new pool construction recovers gradually alongside housing turnover. Ongoing share buybacks and steady dividend growth support mid-single-digit EPS expansion through FY2030.
Mortgage interest rates decline, releasing pent-up demand for new residential pool construction and major backyard renovations. Accelerated contractor adoption of premium variable-speed equipment and private-label water treatment expands branch gross margins, driving robust EPS expansion by FY2030.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 8.3% | $182 | $187 | $192 | $198 | $205 |
| 8.8% | $170 | $174 | $179 | $183 | $189 |
| 9.3% | $160 | $163 | $167 | $171 | $175 |
| 9.8% | $151 | $154 | $157 | $160 | $164 |
| 10.3% | $143 | $145 | $148 | $151 | $154 |
Upcoming earnings date and setup when available.
Рейтинг, который имело опубликованное в каждом месяце издание исследования. Рейтинг сравнивает цену на дату анализа со справедливой стоимостью; он не показывает, оправдалась ли оценка.
| Год | янв. | февр. | март | апр. | май | июнь | июль | авг. | сент. | окт. | нояб. | дек. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |